166 related articles for article (PubMed ID: 38659376)
21. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Cinieri S; Chan A; Altundag K; Vandebroek A; Tubiana-Mathieu N; Barnadas A; Dodyk P; Lazzarelli S; Botha M; Rauch D; Villanova G; Coskun U
Clin Breast Cancer; 2017 Apr; 17(2):91-99.e1. PubMed ID: 27756583
[TBL] [Abstract][Full Text] [Related]
22. A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer.
Zhang J; Wang L; Wang Z; Hu X; Wang B; Cao J; Lv F; Zhen C; Zhang S; Shao Z
Cancer Biol Ther; 2015; 16(2):225-32. PubMed ID: 25648299
[TBL] [Abstract][Full Text] [Related]
23. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
Yoshimoto M; Takao S; Hirata M; Okamoto Y; Yamashita S; Kawaguchi Y; Takami M; Furusawa H; Morita S; Abe C; Sakamoto J
Cancer Chemother Pharmacol; 2012 Aug; 70(2):331-8. PubMed ID: 22526409
[TBL] [Abstract][Full Text] [Related]
24. SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer.
Livingston RB; Barlow WE; Kash JJ; Albain KS; Gralow JR; Lew DL; Flaherty LE; Royce ME; Hortobagyi GN
Breast Cancer Res Treat; 2011 Nov; 130(1):123-31. PubMed ID: 21826527
[TBL] [Abstract][Full Text] [Related]
25. Vinorelbine Plus Gemcitabine or Cisplatin as First-line Treatment of HER2-negative Advanced Breast Cancer.
He K; Wang X; Guan X; Yu Q; Ma Q; Liu Z; Yu Z
Anticancer Res; 2017 Oct; 37(10):5647-5653. PubMed ID: 28982882
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
O'Shaughnessy J; McIntyre K; Wilks S; Ma L; Block M; Andorsky D; Danso M; Locke T; Scales A; Wang Y
JAMA Netw Open; 2021 Apr; 4(4):e214103. PubMed ID: 33877311
[TBL] [Abstract][Full Text] [Related]
27. Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial.
Li DD; Tao ZH; Wang BY; Wang LP; Cao J; Hu XC; Zhang J
NPJ Breast Cancer; 2022 Sep; 8(1):110. PubMed ID: 36127351
[TBL] [Abstract][Full Text] [Related]
28. A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer.
Huang W; Wang C; Shen Y; Chen Q; Huang Z; Liu J; Lin X; Wang L; Wu F; Chen X; Li N; Hong Y; Chen M; Li J; Huang C
BMC Cancer; 2024 Jan; 24(1):39. PubMed ID: 38182995
[TBL] [Abstract][Full Text] [Related]
29. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
30. Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study.
Cazzaniga ME; Cortesi L; Ferzi A; Scaltriti L; Cicchiello F; Ciccarese M; Della Torre S; Villa F; Giordano M; Verusio C; Nicolini M; Gambaro AR; Zanlorenzi L; Biraghi E; Legramandi L; Rulli E;
Breast Cancer Res Treat; 2016 Dec; 160(3):501-509. PubMed ID: 27752847
[TBL] [Abstract][Full Text] [Related]
31. Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
Cabel L; Carton M; Cheaib B; Pierga JY; Dalenc F; Mailliez A; Levy C; Jacot W; Debled M; Leheurteur M; Desmoulins I; Lefeuvre C; Gonçalves A; Uwer L; Ferrero JM; Eymard JC; Petit T; Mouret-Reynier MA; Perrocheau G; Piot I; Pérol D; Simon G; Lerebours F
Breast Cancer Res Treat; 2019 Jan; 173(2):397-406. PubMed ID: 30357526
[TBL] [Abstract][Full Text] [Related]
32. All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial.
Tubiana-Mathieu N; Bougnoux P; Becquart D; Chan A; Conte PF; Majois F; Espie M; Morand M; Vaissiere N; Villanova G
Br J Cancer; 2009 Jul; 101(2):232-7. PubMed ID: 19584872
[TBL] [Abstract][Full Text] [Related]
33. Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study.
Heudel P; Delaloge S; Parent D; Madranges N; Levy C; Dalenc F; Brain E; Uwer L; D'Hondt V; Augereau P; Mailliez A; Perrin C; Frenel JS; Sablin MP; Mouret-Reynier MA; Vermeulin T; Eymard JC; Petit T; Ferrero JM; Ilie S; Goncalves A; Chenuc G; Robain M; Simon G; Perol D
Anticancer Res; 2020 Jul; 40(7):3905-3913. PubMed ID: 32620631
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial.
Munzone E; Regan MM; Cinieri S; Montagna E; Orlando L; Shi R; Campadelli E; Gianni L; Palleschi M; Petrelli F; Bengala C; Generali D; Collovà E; Puglisi F; Cretella E; Zamagni C; Chini C; Ruepp B; Loi S; Colleoni M;
JAMA Oncol; 2023 Sep; 9(9):1267-1272. PubMed ID: 37440239
[TBL] [Abstract][Full Text] [Related]
35. [Efficacy analysis of chemotherapy and endocrine therapy combined with targeted drugs after progression on cyclin-dependent kinase 4/6 inhibitor treatment in hormone receptor positive/human epidermal growth factor receptor 2-low metastatic breast cancer].
Liu B; Yuan Y; Li F; Li JB; Bian L; Wang T; Zhang SH; Jiang ZF
Zhonghua Yi Xue Za Zhi; 2024 May; 104(17):1507-1513. PubMed ID: 38706058
[No Abstract] [Full Text] [Related]
36. [Phase Ⅲ randomized controlled, multicenter, prospective study of recombinant anti-HER2 humanized monoclonal antibody (Cipterbin) combined with vinorelbine in patients with HER2 positive metastatic breast cancer: the HOPES Study].
Bian L; Xu BH; Di LJ; Wang T; Wang XJ; Jiao SC; Yang JL; Tong ZS; Liu J; Feng JF; Liu DG; Yu QT; Liu YP; Ma Y; Yu H; Jiang ZF
Zhonghua Yi Xue Za Zhi; 2020 Aug; 100(30):2351-2357. PubMed ID: 32791810
[No Abstract] [Full Text] [Related]
37. Pegylated liposomal doxorubicin (Duomeisu
Jiang H; Li H; Song G; Di L; Shao B; Yan Y; Liu X; Chen Y; Zhang R; Ran R; Liu Y; Gui X; Wang N; Wang H
Breast Cancer Res Treat; 2023 May; 199(1):67-79. PubMed ID: 36877215
[TBL] [Abstract][Full Text] [Related]
38. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
[TBL] [Abstract][Full Text] [Related]
39. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
40. All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer.
Tawfik H; Rostom Y; Elghazaly H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):913-9. PubMed ID: 23344713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]